Table 2.
Baseline characteristics and univariate analyses of prognostic factors of 69 patients with NPC.
| Characteristic | MMR status n (%) | χ2 | P value | OS | PFS | LRFS | DMFS | |
|---|---|---|---|---|---|---|---|---|
| pMMR | dMMR | P | P | P | P | |||
| Sex | 1.16 | 0.28 | 0.39 | 0.85 | 0.77 | 0.67 | ||
| Male | 25 (71.4) | 28 (82.4) | ||||||
| Female | 10 (28.6) | 6 (17.6) | ||||||
| Age (years) | 2.44 | 0.12 | 0.07 | 0.02 | 0.04 | 0.04 | ||
| <53 | 13 (37.1) | 19 (55.9) | ||||||
| ≥53 | 22 (62.9) | 15 (44.1) | ||||||
| Histological pathology typea | NA | NA | NA | NA | NA | NA | ||
| Type 1 | 0 (0.0) | 0 (0.0) | ||||||
| Type 2 | 35 (100.0) | 34 (100.0) | ||||||
| Type 3 | 0 (0.0) | 0 (0.0) | ||||||
| Clinical stageb | 0.17 | 1.00 | 0.01 | 0.05 | 0.50 | 0.08 | ||
| II | 5 (14.3) | 4 (11.8) | ||||||
| III | 16 (45.7) | 16 (47.1) | ||||||
| IVa | 14 (40.0) | 14 (41.2) | ||||||
| T-categoryb | 0.01 | 0.95 | 0.02 | 0.03 | 0.08 | 0.04 | ||
| T1-2 | 8 (22.9) | 8 (23.5) | ||||||
| T3-4 | 27 (77.1) | 26 (76.5) | ||||||
| N-categoryb | 0.13 | 0.71 | 0.06 | 0.23 | 0.21 | 0.50 | ||
| N0-2 | 29 (82.9) | 27 (79.4) | ||||||
| N3 | 6 (17.1) | 7 (20.6) | ||||||
| Therapy regimens | 0.17 | 0.92 | 0.11 | 0.18 | 0.45 | 0.24 | ||
| IMRT | 8 (22.9) | 9 (26.5) | ||||||
| CCRT | 17 (48.6) | 15 (44.1) | ||||||
| ACCRT | 10 (28.6) | 10 (29.4) | ||||||
| MMR status | NA | NA | 0.06 | 0.09 | 0.95 | 0.02 | ||
| pMMR | NA | NA | ||||||
| dMMR | NA | NA | ||||||
aWHO Classification of Head and Neck Tumours 4th Edition: type 1, Keratinizing squamous cell carcinoma; type 2, Non-keratinizing squamous cell carcinoma; type 3, Basaliod squamous cell carcinoma; bAccording to the AJCC TNM classification of malignant tumours 8th ed.
Abbreviations: NPC: nasopharyngeal carcinoma; MMR: mismatch repair; dMMR: deficient MMR; pMMR: proficient MMR; OS: overall survival; PFS: progression-free survival; DMFS: distant metastasis-free survival; LRFS: local recurrence-free survival; IMRT: intensity-modulated radiotherapy; CCRT: concurrent chemoradiotherapy; ACCRT: asynchronous combination chemoradiotherapy; NA: Not applicable.